The proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the identifier PXD001276 (<http://www.ebi.ac.uk/pride/archive/projects/PXD001276>) The transcriptomic data have been deposited to the GEO repository with the identifier GSE60970 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60970>).

Introduction {#sec001}
============

Multiple myeloma (MM) is an incurable bone marrow disease and the second most common hematological cancer. The median age of onset is 65 years and progression often leads to severe complications including immunodeficiency, osteolytic bone disease and renal failure \[[@pone.0119857.ref001]\]. Although current therapies may improve the patient's survival, disease progression and acquired drug resistance remain unsolved issues. Since the 1960s, the alkylating drug melphalan (L-phenylalanine mustard) has been employed in combination with corticosteroids as first-line therapy for MM \[[@pone.0119857.ref002]\]. Novel agents such as bortezomib and lenalidomide have recently been introduced, but melphalan remains the standard therapy for transplant-ineligible patients and is the basis for high-dose therapy associated with autologous stem cell transplant \[[@pone.0119857.ref003]\]. Melphalan's efficacy has been attributed to its ability to induce cytotoxic interstrand cross-links (ICLs) in DNA \[[@pone.0119857.ref004]\], but it may also induce other lesions in DNA \[[@pone.0119857.ref005]\], RNA, proteins and lipids \[[@pone.0119857.ref006]\]. The mechanisms by which melphalan kills tumor cells thus remain elusive and identifying factors that attenuate melphalan sensitivity is crucial to improving therapeutic outcomes.

Acquired melphalan resistance in MM has been associated with reduced drug uptake \[[@pone.0119857.ref007]\], increased drug detoxification \[[@pone.0119857.ref008],[@pone.0119857.ref009]\], reduced ICL formation and enhanced DNA repair of ICL lesions \[[@pone.0119857.ref010]--[@pone.0119857.ref012]\], modulation of DNA base excision and strand break repair \[[@pone.0119857.ref013],[@pone.0119857.ref014]\], adaptation to reactive oxygen species (ROS) \[[@pone.0119857.ref015]\] and decreased apoptosis \[[@pone.0119857.ref016]\]; however, there are no robust biomarkers that predict melphalan resistance.

Here we have used transcriptomics and proteomics to investigate cellular changes associated with acquired melphalan resistance in the RPMI8226 multiple myeloma cell line. We observed a metabolic switch conforming to the Warburg effect in the melphalan-resistant cell line accompanied by an increased oxidative stress response and enhanced survival and proliferation signaling. The increased survival was partially mediated through VEGF- and IL8-induced PI3K/p38 signaling and upregulated expression of the AKR1C family of aldo-keto reductases. We demonstrate that targeting enzymes within the affected pathways by specific inhibitors can overcome acquired melphalan resistance.

Materials and Methods {#sec002}
=====================

Reagents and antibodies {#sec003}
-----------------------

For Western analysis antibodies to AKR1C2 (H00001646-D01, Abnova), AKR1C3 (H00008644-B01, Abnova), AKR1C4 (H00001109-M01, Novus), AKT1 (\#2967, Cell Signaling), Caspase3 (sc-7148, Santa Cruz), SLC16A3 (OAAB08662, Aviva Systems Biology) PARP-1 (sc-74470, Santa Cruz), STAT3 (sc-81385, Santa Cruz), pSTAT3 (S2690, Sigma) and β-actin (ab8226, Abcam) primary antibodies and HRP-conjugated secondary antibodies (Dako) were used. Melphalan, ursodeoxyholate, indomethacin, flufenamic acid, dichloroacetic acid, 2-deoxy-D-glucose, sodium oxamate, metformin, oligomycin, antimycinA, FLLL31, wortmannin, rapamycin, methyl glyoxal, acetylsalicylic acid, ibuprofen, (Sigma Aldrich), tert-butyl peroxide (Fluka), LY294002, SB203580 and BIRB0796 (Cell Signaling) were used in viability assays.

Cell lines and preparation of cell extracts {#sec004}
-------------------------------------------

MM cell lines RPMI8226 and RPMI8226-LR5 were kindly donated by Prof. William S. Dalton at the H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA. Cells were maintained, treated with melphalan and cell extracts prepared as previously described \[[@pone.0119857.ref013]\].

mRNA isolation and analysis {#sec005}
---------------------------

mRNA was isolated from six batches each of control and melphalan-treated RPMI8226 and RPMI8226-LR5 cells using the mirVana mRNA isolation kit (Ambion). RNA concentration and quality were determined using NanoDrop ND-8000 (NanoDrop Technologies) and Agilent 2100 Bioanalyzer (Agilent). RIN values of RNA samples used for cRNA amplification ranged from 8.5 to 10 (mean = 9.49). The Illumina TotalPrep RNA amplification Kit (Ambion) was used to amplify mRNA for hybridization on Illumina BeadChips. First strand cDNA was synthesized from each mRNA sample. Following second strand synthesis and purification, cRNA was synthesized for 12 hours. Gene expression profiles were measured using Illumina HumanHT-12_V3 Expression BeadChip. Raw data were exported from Illumina GenomeStudio to R using the Bioconductor package \`lumi\`version 2.1.3. \[[@pone.0119857.ref017]\]. Data were quantile normalized and log~2~ transformed. The groups were compared using a t-test with empirical Bayes correction from the Bioconductor package \`Limma\`\[[@pone.0119857.ref018]\]. The fold change was used to demonstrate rate of changes in average gene expressions between studied groups. Statistical analyses were performed using the false discovery rate (FDR) with a significance threshold of 0.01. The transcriptomic data have been deposited to the GEO repository with the identifier GSE60970 \[[@pone.0119857.ref019]\].

Western analysis, viability assay and mROS analysis {#sec006}
---------------------------------------------------

Western analysis and MTT assays were performed as described \[[@pone.0119857.ref013]\]. mROS was analyzed using MitoSOX Red (Molecular Probes) according to the manufacturer's protocol. Briefly, cells (0.5 × 10^6^ cells/ml) were pretreated with inhibitors for 6 h, washed with HBBS and incubated with MitoSOX for 10 min at 37°C. Flow cytometry was performed at 510 nm excitation and 580 nm emissions.

Cytokine and lactate analysis {#sec007}
-----------------------------

Briefly cells (0.5 × 10^6^ cells/ml) were incubated in RPMI1640 medium until they reached approximately 1 × 10^6^ cells/ml and 80% viability. Medium (50 μl) was used for cytokine measurements in duplicates using the Bioplex 27-plex human cytokine kit from BioRad as per manufacturer\'s instructions. Bioplex manager software was used for calculation of cytokine concentrations. Standard curves were optimized by the software and verified manually. Lactate levels were measured using the L-Lactate Assay Kit according to the manufacturer's protocol (Cayman). Extracellular lactate level was measured in medium, intracellular lactate in 15 × 10^6^ cells. Results were normalized and are shown as concentration of lactate/1 × 10^6^ cells.

Stable isotope labeling with amino acids in cell culture (SILAC) and LC-MS/MS analysis {#sec008}
--------------------------------------------------------------------------------------

RPMI8226 and RPMI8226-LR5 cells were grown in light (^12^C6-lysine) and heavy (^13^C6-lysine) medium, respectively (Pierce SILAC protein Quantitation kit-RPMI1640). Sensitive and resistant cells were mixed 1:1 and cell extracts prepared as above. Proteins were separated on 4--12% denaturing NuPAGE (Invitrogen) and stained with Simply Blue^TM^ (Invitrogen). Thirteen bands were excised, reduced and alkylated prior to trypsin in-gel digestion as described \[[@pone.0119857.ref020]\]. Peptides were eluted with 50% acetonitrile in 5% formic acid and lyophilized before MS analysis. LC-MS/MS was conducted on an EASY-nLC (Proxeon) coupled to an LTQ-Orbitrap XL mass spectrometer (Thermo). Reconstituted samples were separated on an in-house 15 cm fused silica column (100 μm i.d., 375 μm o.d.) using a 50 min gradient up to 32% ACN in 0.1% formic acid and 250 nl/min flow rate. MS scans (300--1800 m/z) were acquired at a resolution of 60,000 (m/z 400) in the Orbitrap. During each duty cycle, up to five of the most intense peptides were selected for CID fragmentation in the ion trap. Raw files were processed in MaxQuant v.1.0.13.8, with Mascot searches utilizing human IPI database (version 3.52) containing extra entries for reverse protein sequences. Search criteria included carbamidomethylation as fixed modification, deamidation (NQ) and oxidation (M) as variable modifications, maximum of two missed cleavage sites and MS/MS tolerance of 0.6 Da. FDR thresholds for peptide and protein identifications were set to 1%. A minimum of two unique peptides was specified for protein identifications, with protein quantification requiring at least two ratio measurements. The proteomics data have been deposited to the ProteomeXchange Consortium \[[@pone.0119857.ref021]\] via the PRIDE partner repository with the identifier PXD001276 \[[@pone.0119857.ref022]\].

Statistical analysis {#sec009}
--------------------

Significance and p-value in viability assays were obtained from the GraphPad Prism software (GraphPad Software). Each experiment was conducted in triplicate, data were analyzed using one-way ANOVA and student---Newman-Keuls multiple test, where: ns---p\>0.05, \*- 0.05≥p\>0.01, \*\*- 0.01≥p\>0.001, \*\*\* - p≤ 0.001.

Results {#sec010}
=======

Illumina and SILAC gene expression profiling {#sec011}
--------------------------------------------

To investigate large scale alterations in gene expression accompanying melphalan resistance, we used the multiple myeloma cell line RPMI8226 and its melphalan-resistant derivative LR5. The stable isotope labeling by amino acids in cell culture (SILAC) approach resulted in the identification of 1042 proteins, of which 668 were quantified using MaxQuant (PEP \<0.01) ([S1 Table](#pone.0119857.s001){ref-type="supplementary-material"}). The histogram of the log~2~ SILAC ratios showed a normal distribution centered at zero, supporting similar overall protein loads of the H/L samples ([Fig. 1A](#pone.0119857.g001){ref-type="fig"}). Illumina HumanHT-12_V3 annotation data were used for mapping mRNA expression and led to 4580 identifications with p-values \< 0.05 ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}). We considered differentially expressed genes (DEGs) exhibiting an absolute fold change above 1.25 because the cell lines were isogenic and proliferated similarly. This resulted in 424 and 2842 unique proteins and mRNAs, respectively ([S1](#pone.0119857.s001){ref-type="supplementary-material"}and [S2](#pone.0119857.s002){ref-type="supplementary-material"} Tables), of which 175 proteins and mRNAs overlapped ([Fig. 1B](#pone.0119857.g001){ref-type="fig"}). We observed a high correlation of expression data from the protein and mRNA analyses (up-regulated R^2^ = 0.91, down-regulated R^2^ = 0.72, [Fig. 1C](#pone.0119857.g001){ref-type="fig"}). The most differentially regulated proteins in the SILAC analyses are listed in [Table 1](#pone.0119857.t001){ref-type="table"} together with their corresponding fold changes at the mRNA level.

![SILAC and mRNA quantitative profiling.\
(A), histogram of log~2~ SILAC ratios. (B), Venn diagram of DEGs identified in SILAC and mRNA analyses (threshold 1.25 fold change). (C), Scatter plot illustrating fold change relationships between DEGs identified in SILAC and mRNA analyses. (D), Most affected canonical pathways as identified by IPA analysis of SILAC data (threshold 1.25x change). The orange line represents the ratio of the number of genes represented within each pathway to the total number of genes in the pathway. (E), Distribution of DEGs in GO: biological process categories.](pone.0119857.g001){#pone.0119857.g001}
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###### Most up- and downregulated genes in melphalan-resistant cells as determined from SILAC and Illumina analysis.

![](pone.0119857.t001){#pone.0119857.t001g}

  Gene symbol   Protein name                                                REFSEQ         Fold change SILAC[^a^](#t001fn001){ref-type="table-fn"}   Fold change Illumina[^a^](#t001fn001){ref-type="table-fn"}
  ------------- ----------------------------------------------------------- -------------- --------------------------------------------------------- ------------------------------------------------------------
  AKR1C3        aldo-keto reductase family 1, member C3                     NP_003730      **12,053**                                                **25,507**
  VIM           vimentin                                                    NP_003371      **4,212**                                                 **2,208**
  MACF1         microtubule-actin crosslinking factor 1                     NP_149033      **3,968**                                                 **2,263**
  POLR1A        polymerase (RNA) I polypeptide A, 194kDa                    NP_056240      **3,345**                                                 
  CBR1          carbonyl reductase 1                                        NP_001748      **2,839**                                                 1,159
  UAP1          UDP-N-acteylglucosamine pyrophosphorylase 1                 NP_003106      **2,836**                                                 **1,654**
  KHDRBS1       KH domain containing, RNA bindingSAM68                      NP_006550      **2,796**                                                 1,193
  ANXA5         annexin A5                                                  NP_001145      **2,789**                                                 **1,859**
  G3BP1         GTPase activating protein (SH3 domain) binding protein 1    NP_005745      **2,759**                                                 -1,192
  KPNA2         karyopherin alpha 2 (RAG cohort 1, importin alpha 1)        NP_002257      **2,549**                                                 1,093
  PRPF19        PRP19/PSO4 pre-mRNA proc.factor 19                          NP_055317      **2,483**                                                 -1,311
  PSME3         proteasome (prosome, macropain) activator subunit 3         NP_789839      **2,441**                                                 1,169
  ARD1A         ARD1 homolog A, N-acetyltransferase (S. cerevisiae)         NP_003482      **2,307**                                                 1,212
  HNRNPA3       heterogeneous nuclear ribonucleoprotein A3                  NP_919223      **2,272**                                                 **1,945**
  HSPA8         heat shock 70kDa protein 8                                  NP_006588      **2,237**                                                 1,158
  XPO5          exportin 5                                                  NP_065801      **2,199**                                                 **1,287**
  ABCE1         ATP-binding cassette, sub-family E (OABP), member 1         NP_001035809   **2,177**                                                 **1,721**
  PPID          peptidylprolyl isomerase D                                  NP_005029      **2,162**                                                 -1,015
  ACTN4         actinin, alpha 4                                            NP_004915      **2,156**                                                 **1,396**
  CKAP5         cytoskeleton associated protein 5                           NP_001008938   **2,136**                                                 1,237
  G6PD          glucose-6-phosphate dehydrogenase                           NP_000393      **2,101**                                                 **1,935**
  DDX19A        DEAD (Asp-Glu-Ala-As) box polypeptide 19A                   NP_060802      **2,088**                                                 **1,467**
  NAPG          splicing factor proline/glutamine-rich                      NP_003817      **2,054**                                                 **2,813**
  MYO1C         N-ethylmaleimide-sensitive factor attachment protein γ      NP_001074248   **2,025**                                                 
  PTBP1         polypyrimidine tract binding protein 1                      NP_002810      **2,022**                                                 1,328
  CBR3          carbonyl reductase 3                                        NP_001227      **2,019**                                                 **1,430**
  LRBA          LPS-responsive vesicle trafficking, beach and anchor c.     NP_006717      **2,007**                                                 **1,670**
  RRBP1         ribosome binding protein 1 homolog 180kDa (dog)             NP_001036041   **-2,618**                                                **-1,773**
  SERPINH1      serpin peptidase inhibitor, clade H member 1                NP_001226      **-2,639**                                                -1,609
  MESDC2        mesoderm development candidate 2                            NP_055969      **-2,733**                                                
  FN1           fibronectin 1                                               NP_997647      **-2,849**                                                
  SFN           stratifin                                                   NP_006133      **-2,859**                                                **-2,069**
  PCK2          phosphoenolpyruvate carboxykinase 2 (mitochondrial)         NP_004554      **-2,894**                                                -1,22
  NSDHL         NAD(P) dependent steroid dehydrogenase-like                 NP_001123237   **-2,904**                                                -1,155
  DCI           dodecenoyl-Coenzyme A delta isomerase                       NP_001910      **-2,956**                                                **-2,122**
  MAN2A1        mannosidase, alpha, class 2A, member 1                      NP_002363      **-3,007**                                                **-1,378**
  STT3B         STT3, subunit of oligosaccharyltransferase compl. hom. B    NP_849193      **-3,016**                                                **-1,356**
  PDIA5         protein disulfide isomerase family A, member 5              NP_006801      **-3,019**                                                **-1,946**
  DNAJB11       DnaJ (Hsp40) homolog, subfamily B, member 11                NP_057390      **-3,045**                                                -1,130
  ERP44         endoplasmic reticulum protein 44                            NP_055866      **-3,070**                                                
  DDOST         dolichyl-diphosphooligosaccharide-protein glycosyltransf.   NP_005207      **-3,163**                                                **-1,347**
  PDIA4         protein disulfide isomerase family A, member 4              NP_004902      **-3,271**                                                **-1,835**
  PDIA6         protein disulfide isomerase family A, member 6              NP_005733      **-3,419**                                                **-2,008**
  ERP29         endoplasmic reticulum protein 29                            NP_006808      **-3,487**                                                **-2,231**
  IGF2R         insulin-like growth factor 2 receptor                       NP_000867      **-3,530**                                                1,248
  STAT1         signal transducer and activator of transcription 1, 91kDa   NP_009330      **-3,536**                                                -1,883
  ASS1          argininosuccinate synthetase 1                              NP_000041      **-3,543**                                                -2,069
  STOML2        stomatin (EPB72)-like 2                                     NP_038470      **-3,594**                                                **-1,335**
  CKB           creatine kinase, brain                                      NP_001814      **-3,615**                                                -1,126
  CANX          calnexin                                                    NP_001019820   **-3,675**                                                **-3,408**
  IDH2          isocitrate dehydrogenase 2 (NADP+), mitochondrial           NP_002159      **-3,819**                                                **-1,977**
  EPHX1         epoxide hydrolase 1, microsomal (xenobiotic)                NP_000111      **-3,983**                                                -1,13
  PHGDH         phosphoglycerate dehydrogenase                              NP_006614      **-6,014**                                                **-4,343**
  C2orf30       endoplasmic reticulum lectin 1                              NP_056516      **-8,235**                                                -1,340
  PDIA2         protein disulfide isomerase family A, member 2              NP_006840      **-14,947**                                               
  MYO6          myosin VI                                                   NP_004990      **-20,807**                                               
  MX1           myxovirus resistance 1, interferon-inducible protein p78    NP_002453      **-39,202**                                               **-12,073**

^a^Statistically significant values are highlighted in bold.

Melphalan-resistant RPMI8226 cells display altered expression of metabolic enzymes conforming to the Warburg effect {#sec012}
-------------------------------------------------------------------------------------------------------------------

To search for modified biological pathways in the resistant cells, gene identifiers in the SILAC dataset were mapped in the Ingenuity Knowledge Base, entered into Ingenuity Pathway Analysis (IPA) and plotted onto canonical pathways. Glycolysis was identified as the most significantly altered pathway (p = 1.31 × 10^-9^), and several other respiratory metabolism pathways were also significantly altered ([Fig. 1D, E](#pone.0119857.g001){ref-type="fig"}). Specifically, most of the glycolytic and pentose phosphate pathway (PPP) enzymes were up-regulated in the resistant cells, whereas the tri-carboxylic acid (TCA) cycle and electron transport chain proteins were down-regulated ([Fig. 2](#pone.0119857.g002){ref-type="fig"}). Such a metabolic switch is a characteristic feature of the Warburg effect \[[@pone.0119857.ref023]\], which is considered a survival mechanism in cancerous tissues \[[@pone.0119857.ref024]\] that also mediates resistance to apoptosis \[[@pone.0119857.ref025]\] and to oxidative stress \[[@pone.0119857.ref026]\]. The underlying mechanisms leading to the Warburg effect are not well understood. However, a number of oncogenes, including c-MYC, are known to enhance the expression of glycolytic enzymes, such as lactate dehydrogenase (LDHA) \[[@pone.0119857.ref027]\]. Although c-MYC was not quantified by SILAC, its mRNA was 1.8-fold up-regulated in the melphalan-resistant cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}) and 1.5-fold upregulated as quantified by western blot (data not shown).

![Overview of DEGs in the glycolytic and oxidative metabolic pathways.\
The observed up-regulation of factors in the glycolytic- and pentose phosphate pathways and down-regulation of factors in the TCA cycle and the mitochondrial electron transport chain conform to a Warburg type metabolic switch.](pone.0119857.g002){#pone.0119857.g002}

Melphalan-resistant cells display markedly increased sensitivity towards inhibitors targeting turnover of glycolytic intermediates {#sec013}
----------------------------------------------------------------------------------------------------------------------------------

To further analyze the significance of carbohydrate metabolism in melphalan resistance, sensitive and resistant cells were grown in the presence or absence of glucose. Glucose deprivation had a significantly stronger growth-inhibitory effect in resistant cells compared to sensitive cells ([Fig. 3A](#pone.0119857.g003){ref-type="fig"}). We then subjected both cell lines to treatment with enzyme inhibitors that target different steps in glycolysis and the PPP. 2-deoxy-D-glucose (2-DG) inhibits hexokinase (HK) and phosphoglucoisomerase (GPI) and thus funneling of precursors into both glycolysis and PPP. Blocking glycolysis causes ATP depletion, cell cycle arrest and cell death, while blocking PPP inhibits NADPH synthesis and reduces the antioxidant capacity of the cells. 6-aminonicotinamide (6-AN) potently inhibits glucose-6-phosphate dehydrogenase (G6PD) and selectively inhibits PPP. G6PD was more than two-fold up-regulated in the melphalan-resistant cells according to the SILAC analyses. Sodium oxamate (SO) inhibits the conversion of pyruvate to lactate by LDHA, thus inhibiting glycolysis by depleting NAD^+^ \[[@pone.0119857.ref028]\]. Finally, dichloroacetate (DCA) inhibits all pyruvate dehydrogenase kinase (PDK) isoenzymes, thus increasing the activity of pyruvate dehydrogenase (PDH) and increasing the acetyl-CoA introduced into the TCA cycle \[[@pone.0119857.ref029]\]. All of these inhibitors had a significantly stronger growth-inhibitory effect upon melphalan-resistant cells and this was also observed when inhibitors were combined with 2.5 μM melphalan ([Fig. 3A](#pone.0119857.g003){ref-type="fig"}). This corroborates that a metabolic switch towards aerobic glycolysis contributes to the melphalan-resistant phenotype.

![Melphalan-resistant cells are selectively sensitive to inhibitors targeting enzymes in glycolytic- and pentose phosphate pathways as well as complexes in the mitochondrial electron transport chain.\
(A), Bar diagram illustrating effect of inhibitors targeting various enzymes in carbohydrate metabolism (2-DG, 1 mM, 6-AN, 1 mM, SO, 20 mM, DCA, 10 mM) when administered in the presence or absence of 2.5 μM melphalan (Mel). (B), DCA treatment selectively mediates increased mitochondrial ROS in the resistant cells. (C), Western analysis of the apoptotic markers PARP1 (upper panels) and caspase-3 (bottom panels) illustrating increased cleavage of both proteins subsequent to co-treatment of the resistant cells with DCA and melphalan. (D), Bar diagram illustrating effect of inhibitors targeting the mitochondrial electron transport chain or ATP synthesis (metformin, 3 mM, antimycin A, 30 μM, oligomycin, 10 μM) and the general pro-oxidant tBHP (20 μM) when administered in the presence or absence of 2.5 μM melphalan. (E), Western analysis of AKT1 and pAKT1 in the sensitive and resistant cells.](pone.0119857.g003){#pone.0119857.g003}

Melphalan-resistant cells display increased tolerance to overall oxidative stress, but are sensitive to mitochondrial electron transport inhibitors {#sec014}
---------------------------------------------------------------------------------------------------------------------------------------------------

DCA mediated the largest selective effect against the resistant cells ([Fig. 3A](#pone.0119857.g003){ref-type="fig"}). This inhibitor does not directly target glycolytic or PPP enzymes. We thus measured mitochondrial ROS subsequent to DCA-treatment to examine whether increased metabolic flux into mitochondria was less tolerated by the melphalan-resistant cells. As illustrated in [Fig. 3B](#pone.0119857.g003){ref-type="fig"} increased mitochondrial ROS was selectively induced in the melphalan-resistant cells subsequent to DCA-treatment. Western analysis of PARP1 and caspase-3 revealed weak induction of PARP1 cleavage in both cell lines subsequent to DCA treatment, whereas combined DCA/melphalan treatment mediated markedly increased cleavage of both PARP1 and caspase-3 in the melphalan-resistant cells ([Fig. 3C](#pone.0119857.g003){ref-type="fig"}).

Increased mitochondrial stress may reduce the mitochondrial capability to regenerate NAD^+^ to support glycolytic ATP-production. This would more severely impact the resistant cells given their increased dependence upon glycolytic ATP-production. We tested this by treating the cells with electron transport chain inhibitors (metformin and antimycin A) or with the ATP synthase inhibitor oligomycin. Metformin and antimycin A were more toxic to the resistant cells both in the presence and absence of 2.5 μM melphalan, whereas oligomycin was more toxic to the sensitive cells under both conditions ([Fig. 3D](#pone.0119857.g003){ref-type="fig"}). Oligomycin inhibits mitochondrial ATP synthase and does not directly affect the NAD^+^-generating steps. These results further confirm the increased dependence of the melphalan-resistant cells to glycolytic ATP production.

The melphalan-resistant cells were also more tolerant towards the unspecific pro-oxidant tert-butyl hydroperoxide (t-BHP) ([Fig. 3D](#pone.0119857.g003){ref-type="fig"}). The cytotoxic effects of t-BHP have been shown to be counteracted by activation of the NRF2-mediated stress response \[[@pone.0119857.ref030]\]. In affirmation of this, we observed that NRF2 mRNA was significantly up-regulated (1.5 ×) in the resistant cells and the NRF2-mediated oxidative stress response was reported to be significantly (p = 1.03 × 10^-4^) modulated in the IPA analysis. From these results we concluded that the melphalan-resistant cells are more tolerant of oxidative stress, mediated at least partially by NRF2, but are selectively sensitive towards drugs that inhibit NAD^+^ regeneration.

Lactate accumulation and IL8/VEGF signaling contribute to increased survival in the melphalan-resistant cells {#sec015}
-------------------------------------------------------------------------------------------------------------

The observed metabolic shift should result in increased lactate production in the resistant cells to regenerate NAD^+^ and facilitate glycolytic ATP production. We found a higher intracellular but lower extracellular lactate content in the melphalan-resistant cells ([Fig. 4A](#pone.0119857.g004){ref-type="fig"}), indicating that lactate is retained in the melphalan-resistant cells. Lactate is exported from cells by the monocarboxylate transporters of the SLC16 family, of which SLC16A3 (MCT4) is the major lactate transporter in leukocytes \[[@pone.0119857.ref031]\]. SLC16A3 was 4.7-fold down-regulated at the mRNA level in the melphalan-resistant cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}), but was not quantified in the SILAC analysis. Western analysis of SLC16A3 revealed no significant reduction in the melphalan-resistant cells ([Fig. 4B](#pone.0119857.g004){ref-type="fig"}).

![Lactate accumulates in melphalan resistant cells and may mediate increased IL8- and VEGF signaling.\
(A), Bar diagrams demonstrating significantly increased lactate accumulation in melphalan-resistant cells (left panel), and significantly lower lactate in the extracellular medium (right panel). (B), Western analysis revealed no significant change in expression of the major lactate exporter SLC16A3 (C), Bioplex cytokine profiling demonstrated markedly elevated synthesis of IL8 (left panel) and VEGF (right panel) in the melphalan-resistant cells. (D), Western analysis demonstrated no induced activation of STAT3 in the melphalan resistant cells as probed with anti-pSTAT3 (Y705 antibody). (E), Bar diagram illustrating the effects of various inhibitors targeting STAT3 (FLLL31, 3μM), PI3-kinases (LY294002, 10 μM, wortmannin, 2 μM, rapamycin, 5nM) and p38 MAP kinases (SB203580, 10 μM, BIRB796, 10 μM). (F), Western analysis demonstrating down-regulation of p-AKT1 and AKT1 in the melphalan-resistant cells.](pone.0119857.g004){#pone.0119857.g004}

Lactate can serve as metabolic fuel in certain cell types via the proposed cytoplasmic/mitochondrial lactate shuttle \[[@pone.0119857.ref032],[@pone.0119857.ref033]\]. In addition, lactate may act as a signaling molecule inducing a pseudo-hypoxic condition leading to up-regulation of NF-κB/IL-8 and pro-angiogenic VEGF \[[@pone.0119857.ref034]\]. The latter is also supported by the co-regulated expression of lactate dehydrogenase and VEGF in tumor cells \[[@pone.0119857.ref035]\]. We found that IL-8 was 4.4-fold up-regulated at the mRNA level ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}) and both IL-8 and VEGF secretion were increased (\>12- and 1.7-fold, respectively) in the melphalan-resistant cells ([Fig. 4C](#pone.0119857.g004){ref-type="fig"}). IL-8 and VEGF can mediate pro-survival and proliferation responses through alternative downstream pathways. One of the downstream effectors of IL-8 is STAT3 \[[@pone.0119857.ref036]\], which has emerged as a potential oncogene target in many solid and hematologic cancers, including MM \[[@pone.0119857.ref037]\]. However, we found no difference in STAT3 mRNA levels in the sensitive and resistant cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}). Moreover, western analysis revealed no induction of total- or phosphorylated (pY705) STAT3 protein in the resistant cells ([Fig. 4D](#pone.0119857.g004){ref-type="fig"}). We also subjected the cells to treatment with the STAT3 inhibitor FLLL31, and found that the inhibitor selectively reduced viability in the melphalan-sensitive cells both in the absence and presence of 2.5 μM melphalan ([Fig. 4E](#pone.0119857.g004){ref-type="fig"}). An explanation to this could be that alternative survival pathways are up-regulated in the melphalan-resistant cells making them less dependent on STAT3 signaling.

To further investigate the impact of IL-8/VEGF signaling, we subjected the cells to inhibitors that target downstream effectors of IL-8 and VEGF, specifically within the PI3K and p38 MAPK signaling pathways. LY294002 and wortmannin are kinase inhibitors that target PI3K, and rapamycin inhibits mTOR downstream of PI3K. All the PI3K/mTOR inhibitors were more cytotoxic to the melphalan-resistant cells and abolished the selective proliferation advantage of the resistant cells observed with 2.5 μM melphalan alone ([Fig. 4E](#pone.0119857.g004){ref-type="fig"}). The mTOR pathway has been suggested to be a potential therapeutic target in myeloma characterized by up-regulated AKT1 \[[@pone.0119857.ref038]\]. We did not observe a difference in mTOR and AKT1 mRNA levels between melphalan-resistant and sensitive cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}) and could not quantify the proteins by SILAC. We therefore measured AKT1 by western blot and found that AKT1 and pAKT1 expression is decreased in melphalan-resistant cells ([Fig. 4F](#pone.0119857.g004){ref-type="fig"}). Thus, mTOR inhibition does not fully explain the selective cytotoxicity of these inhibitors in melphalan-resistant cells.

The p38 MAPK inhibitor SB203580 is strictly selective for p38α and β, whereas BIRB0796 inhibits p38α, β, δ and γ \[[@pone.0119857.ref039]\]. In addition, SB203580 inhibits CK1, GSK3, RIP2 and GAK, and BIRB0796 inhibits JNK2 \[[@pone.0119857.ref038]\]. BIRB796 was much more cytotoxic in the melphalan-resistant cells, having little effect on the resistant cells, whereas SB203580 showed no selectivity towards either cell line when administered alone. However, both inhibitors reversed the selective growth advantage of the melphalan-resistant cells in 2.5 μM melphalan ([Fig. 4B](#pone.0119857.g004){ref-type="fig"}). Taken together, the selective cytotoxicity of inhibitors acting downstream of IL-8/VEGF supports a role of IL-8/VEGF-signaling in acquired melphalan resistance in MM.

A potential role of aldo-keto reductases in melphalan resistance {#sec016}
----------------------------------------------------------------

The aldo-keto reductase AKR1C enzymes constitute a family of oxidoreductases that catalyze NADPH-dependent reduction of a wide variety of substrates \[[@pone.0119857.ref040]\]. Here, AKR1C1--3 regulate ligand occupancy and *trans*-activation of androgen-, estrogen- and progesterone receptors, the peroxisome proliferator-activated receptor (PPARγ) as well as the prostaglandin metabolism \[[@pone.0119857.ref041]\]. AKRC1 members displayed the most pronounced up-regulated expression in both the SILAC and mRNA profiling analyses ([Fig. 5A](#pone.0119857.g005){ref-type="fig"}). Due to their extensive sequence homology (84% to 98%), AKR1C1--4 were collectively reported as 12-fold up-regulated in SILAC. AKR1C2, 3 and 4 mRNA were 37-, 25- and 22-fold up-regulated, respectively. We also measured AKR1C2, C3 and C4 by western blot and observed the most prominent up-regulation of AKR1C2 and C3 (15.6- and 28.2-fold, respectively, [Fig. 5A, B](#pone.0119857.g005){ref-type="fig"}). Moreover, enzyme levels did not increase in either cell line after 50 μM melphalan treatment ([Fig. 5B](#pone.0119857.g005){ref-type="fig"}), indicating that their up-regulation is a result of adaptation to prolonged treatment with low dose melphalan rather than an immediate stress response mediated by short time exposure to high dose melphalan.

![Aldo-keto reductases contribute to melphalan resistance in MM cells.\
(A), Diagram showing markedly up-regulated levels of the AKR1C family in both SILAC and mRNA analyses, whereas members of other AKR subfamilies are not significantly altered. (B), Western analysis confirmed up-regulation of AKR1C2 and C3, but not C4. (C), Bar diagram illustrating the effects of AKR inhibitors flufenamic acid (FA, 70 μM), ursodeoxycholate (UDC, 16 μM) and indomethacin (IM, 16 μM) when administered in the presence or absence of 2.5 μM melphalan. (D), Bar diagram illustrating that co-treatment of the myeloma cells with NSAIDs acetylsalisylic acid (ASA) or ibuprofen (Ibu) with melphalan does not reverse the melphalan-resistant phenotype. (E), Western analysis demonstrating strong induction of AKR1C3 and a weaker induction of AKR1C2 in the melphalan-sensitive cells (upper panel) subsequent to 20 h incubation in various concentrations of methyl glyoxal (MG). MG treatment did not affect the AKR1C levels in the resistant cells (lower panel). (F), Bar diagram illustrating that that MG pretreatment (1μM) induced a melphalan-resistant phenotype in the parental RPMI8226 cells similar to that of the resistant LR5 cells.](pone.0119857.g005){#pone.0119857.g005}

To explore the potential role of AKR1C2 and C3 in the melphalan resistance mechanism, melphalan-sensitive and-resistant cells were treated with aldo-keto reductase inhibitors. Flufenamic acid (FA) is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory and antipyretic properties and acts as a broad-spectrum AKR1C inhibitor. In addition it modulates several channel activities and is an activator of AMP-activated protein kinase \[[@pone.0119857.ref042]\]. Indomethacin (IM) is an NSAID commonly used to reduce fever and pain by inhibiting the production of prostaglandins, and inhibits AKR1C3 much more potently than AKRC1 and AKRC2 \[[@pone.0119857.ref043],[@pone.0119857.ref044]\]. IM and FA are also nanomolar and micromolar inhibitors, respectively, of COX-1/2 (PTGS1/2) \[[@pone.0119857.ref045]\]. Previous work suggests, however, that the antiproliferative effect of IM upon myeloma cells is independent of COX-2 \[[@pone.0119857.ref046]\]. Notably FA and IM were moderately selectively cytotoxic to the melphalan-resistant cells when administered alone ([Fig. 5C](#pone.0119857.g005){ref-type="fig"}, left panel). When administered together with melphalan, both inhibitors markedly reversed the resistant phenotype ([Fig. 5C](#pone.0119857.g005){ref-type="fig"}, right panel). To further investigate the specific role of AKR1C in the melphalan-resistant cells we also tested the non-NSAID drug ursodeoxycholate (UDC). UDC is a bile acid drug that reduces cholesterol absorption and is used to treat primary biliary cirrhosis. It inhibits both AKR1C2 and C3 and has been shown to have pro- and anti-apoptotic properties depending on the cell lines and experimental systems employed \[[@pone.0119857.ref047],[@pone.0119857.ref048]\]. Importantly, UDC mediated a nearly complete reversal of the melphalan-resistant phenotype, similar to that seen with FA ([Fig. 5C](#pone.0119857.g005){ref-type="fig"}, right panel). These results strongly suggest that AKR1C2 and C3 contribute to melphalan resistance in the myeloma cells. However, to further investigate whether a general effect mediated by NSAID treatment was involved in reversal of resistance, the cells were also treated with acetylsalicylic acid or ibuprofen. As demonstrated in [Fig. 5D](#pone.0119857.g005){ref-type="fig"}, such treatment did not mediate any change in the relative resistance of the myeloma cells, further substantiating that FA and IM primarily affect melphalan resistance by AKR1C inhibition.

In a recent study of aldehyde toxicity in neuroblastoma cells, Lyon et al. \[[@pone.0119857.ref049]\] demonstrated that the AKR1C3 protein level could be induced by short-time treatment with sub-lethal doses of either methyl glyoxal or 4-hydroxy-2-nonenal (4HNE). These reactive aldehydes are increased in several neurodegenerative diseases \[[@pone.0119857.ref050]\] and recombinant AKR1C1--3 have been shown to possess high specific activities against 4HNE \[[@pone.0119857.ref051]\]. Incubation of the melphalan-sensitive and-resistant cells in 1 μM methyl glyoxal for 24 h mediated a strong up-regulation of AKR1C3 in the melphalan-sensitive cells whereas the AKR1C3 level remained unaltered in the resistant cells. AKR1C2 was also up-regulated by the pretreatment, but much weaker than AKR1C3 ([Fig. 5E](#pone.0119857.g005){ref-type="fig"}). The treatment did not mediate any cytotoxic effect in the cells ([Fig. 5F](#pone.0119857.g005){ref-type="fig"}). However, subsequent treatment of the cells in 2.5 μM melphalan demonstrated that the methyl glyoxal pretreatment mediated a resistant phenotype in the parental RPMI8226 cells resembling that of the LR5 derivative ([Fig. 5F](#pone.0119857.g005){ref-type="fig"}). These results corroborate the inhibitor studies and support a role of AKR1C aldo-keto reductases in mediating melphalan resistance in the myeloma cells.

Discussion {#sec017}
==========

MM is a complex and heterogeneous disease and as such, many factors likely contribute to acquired melphalan resistance. Here we used a transcriptomic and proteomic approach to identify key proteins involved in melphalan resistance in isogenic myeloma cell lines. We thereby demonstrated an active involvement of a metabolic switch in melphalan-resistant cells towards aerobic glycolysis accompanied by an increased tolerance towards oxidative stress. Aerobic glycolysis (Warburg effect) has been largely ignored in cytostatic resistance research, but several recent findings indicate that combining cytostatics with targeted inhibition of aberrant cellular metabolism may overcome chemorefractoriness \[[@pone.0119857.ref052]\]. We similarly targeted the glycolytic pathway with 2-DG, 6-AN and SO and found that they were selectively cytotoxic to melphalan-resistant cells. 2-DG has recently been implemented in phase-I clinical trials in patients with advanced solid tumors \[[@pone.0119857.ref053]\] and its cytotoxicity has been partially attributed to glycolytic inhibition.

DCA was also selectively cytotoxic to the melphalan-resistant cells, and this is corroborated by Sanchez *et al*., who demonstrated a selective effect of DCA in multiple myeloma cell lines having high aerobic glycolysis \[[@pone.0119857.ref054]\]. DCA also increased the sensitivity of these cells towards the proteasome inhibitor bortezomib. ROS induction has been demonstrated to play a critical role in bortezomib-induced apoptosis by disrupting the mitochondrial membrane potential \[[@pone.0119857.ref055]\], and DCA has been shown to synergistically inhibit proliferation in melanoma cells with induced mitochondrial ROS \[[@pone.0119857.ref056]\]. Melphalan and other DNA cross-linkers increase mitochondrial ROS in HeLa and HCT cells \[[@pone.0119857.ref057]\] and oxidative stress has been shown to increase melphalan cytotoxicity in chronic myeloid leukemia cells \[[@pone.0119857.ref058]\]. Thus, DCA could potentiate the effects of melphalan (as well as other cytostatic drugs) by inducing cellular oxidative stress, possibly because the mitochondrial metabolism is down-regulated to counterbalance the oxidative stress induced by continuous drug exposure.

In addition to mediating increased mitochondrial ROS, DCA also depletes substrate from the NAD^+^-generating LDHA step. This slows glycolytic ATP production, rendering the melphalan-resistant cells more sensitive to treatment. The increased reliance of NAD^+^-dependent aerobic glycolysis of the melphalan-resistant cells is also supported by the selective effect of the electron transport chain inhibitors metformin and antimycin A, which target the NAD^+^-generating steps. Metformin is well tolerated and widely used in the treatment of diabetes, and it has been shown to suppress breast and pancreatic tumor development and reprogram ovarian and breast cancer cells to a non-cancerous state \[[@pone.0119857.ref059]--[@pone.0119857.ref063]\]; however, the molecular mechanisms by which metformin displays an anti-cancer effect and is selectively cytotoxic to melphalan-resistant myeloma cells require further study.

Both IL-8 and VEGF are important mediators of hypoxia and oxidative stress signaling that stimulate proliferation and survival of MM cells \[[@pone.0119857.ref064]\]. In addition, IL-8 is a potent pro-inflammatory cytokine. Downstream signaling involves complex kinase networks including MAPKs, PI3Ks and PKC \[[@pone.0119857.ref036]\]. The two PI3K inhibitors LY294002 and wortmannin were selectively cytotoxic to the melphalan-resistant cells. LY294002 broadly targets PI3Ks and has been shown to inhibit CK2, mTOR and GSK3B \[[@pone.0119857.ref065]\], while wortmannin targets PI3K-C2β and weakly inhibits mTOR and DNA-PK \[[@pone.0119857.ref066],[@pone.0119857.ref067]\]. The highly specific mTOR-inhibitor rapamycin was also selectively cytotoxic to the resistant cells. Rapamycin inhibits mTORC1 and may also inhibit mTORC2 in some cell types \[[@pone.0119857.ref068]\]. In the melphalan-resistant cells, mTOR signaling is apparently not AKT dependent, since AKT1- and pAKT1-levels were both reduced. Moreover, PTEN, which negatively regulates AKT, was more than twofold up-regulated at the mRNA level in the resistant cells. AKT1-independent activation of mTOR has been reported in several cell types, including B-lymphocyte cell lines \[[@pone.0119857.ref069]\] and follicular lymphoma cells \[[@pone.0119857.ref070]\]. In the tumor syndrome tuberous sclerosis (TSC) mTOR is indirectly activated by MAPK-mediated phosphorylation of TSC1 and 2 that alleviates inhibition of mTOR \[[@pone.0119857.ref071]\]. Notably we find that both TSC1 and 2 are significantly down-regulated at the mRNA level in the resistant cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}), potentially contributing to increased functional mTOR. Recent studies have assigned a central role of mTOR2C in the control of metabolic reprogramming in cancer cells. This function is AKT-independent and rather involves up-regulation of c-MYC \[[@pone.0119857.ref072],[@pone.0119857.ref073]\], which was found to be 1.8-fold up-regulated at the mRNA level in the resistant cells. In addition, the glucocorticoid-stimulated kinase SGK1, which is a downstream target of mTORC2 and an important mediator of AKT-independent mTOR signaling \[[@pone.0119857.ref074]\] was fourfold up-regulated at the mRNA level in the melphalan-resistant cells ([S2 Table](#pone.0119857.s002){ref-type="supplementary-material"}).

The p38MAPK inhibitors SB203580 and BIRB796 were both differently cytotoxic to the cell lines. These inhibitors also exhibit different specificities, with SB230580 inhibiting p38α and β, as well as CK1, GSK3, RIP2 and GAK, while BIRB796 inhibits p38α, β, γ and δ as well as JNK2. The overlapping specificities of the inhibitors as well as the inherent complexity and crosstalk between the various signaling pathways renders elucidation of the exact mechanisms involved to be extremely challenging; however, the selective cytotoxicity of BIRB796 towards the melphalan-resistant cells warrant further investigation into the involvement of JNK2 in melphalan resistance. JNK2 has a central role in stress signaling, including oxidative stress, and also mediates secretion of pro-inflammatory IL-8, thus potentially forming an autocrine stimulatory loop in the melphalan-resistant cells.

The involvement of AKR1C enzymes in melphalan resistance was substantiated by inhibitor studies as well as the ability of mehyl glyoxal-induced AKR1C3 to induce melphalan-resistance in the parental RPMI8226 cells. The AKR1C subfamily plays essential roles in the metabolism of steroid hormones and bile acids, and is involved in the pre-receptor regulation of nuclear and membrane-bound receptors \[[@pone.0119857.ref075]\]. Dysregulated AKR1C2 and C3 expression has been linked to the development of prostate, breast and endometrial carcinomas as well as leukemias, likely due to their ability to modify steroid hormones and prostaglandins (PDGs) \[[@pone.0119857.ref075]\]. Moreover, AKR1C3 has been identified as a potential therapeutic target in leukemia because its PGD2 reductase activity may prevent cell differentiation \[[@pone.0119857.ref076]\]. This activity also prevents formation of the pro-apoptotic 15-deoxy-PGJ2 \[[@pone.0119857.ref077]\]. In a recent drug screen to identify specific AKR1C3 inhibitors, tetracycline was initially identified as a potential AKR1C3-selective inhibitor. However subsequent analysis by mass spectrometry and NMR revealed that the active inhibitor was a breakdown product of tetracycline, (4-methyl(de-dimethylamine)-tetracycline (4-MDDT). Treatment of leukemia cells with 4-MDDT did not recapitulate the anti-leukemic property of pan-AKR1C inhibitors, suggesting that multiple AKR1C inhibition is likely required to elicit an anticancer effect in leukemia \[[@pone.0119857.ref078]\], in agreement with our findings. In addition to endogenous substrates, AKR1C enzymes have been implicated in the metabolism of several exogenous substrates, including drugs, carcinogens and reactive aldehydes such as 4-hydroxynonenal (4HNE) \[[@pone.0119857.ref049]\]. AKR1C1--3 has been shown to possess a high specific activity for 4HNE reduction \[[@pone.0119857.ref051]\], one of the most cytotoxic products of lipid peroxidation that is likely formed by melphalan-induced cellular peroxide \[[@pone.0119857.ref079]\] and increased plasma lipid peroxidation. A potential role of AKR1C1--3 in melphalan resistance could thus be a result of 4HNE processing. Although currently speculative, the AKR1C enzymes might also have a more subtle role in regulating the redox balance of cells under oxidative stress. They act primarily as reductases *in vivo*, (*K* ~*d*~ for NADPH in the nanomolar range) and could potentially contribute to influence the NADPH/NADP^+^ balance. Since NADPH potently inhibits NAD^+^-dependent oxidation reactions at low μM concentrations, such regulation could ensure sufficient NAD^+^ to allow active glycolytic ATP-generation in the melphalan-resistant cells.

Conclusions {#sec018}
===========

Our results reveal the presence of several previously unrecognized mechanisms for acquired drug resistance against melphalan. The SILAC profiling approach identified a switch in metabolism towards aerobic glycolysis as well as modulated oxidative stress signaling in the resistant cells. The metabolic switch was not evident from the mRNA results alone and underscores the power of quantitative proteomic profiling to identify alterations in biological pathways under significant translational control, such as metabolic pathways during chronic stress \[[@pone.0119857.ref080]\]. The present in-depth analysis of a melphalan-sensitive cell line and its resistant derivative highlights several promising targets within metabolic and oxidative stress response pathways that should be further explored to overcome melphalan resistance in MM. Such studies are now in progress in our laboratory.
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###### Differentially expressed mRNAs in melphalan-resistant and-sensitive RPMI8226 cells as determined from Illumina analysis.
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